RAPIVAB (peramivir injection)
Rapivab is to be given by infusion under medical supervision in a hospital setting or similar. Please contact your doctor or Healthcare Professional if you have any questions about this medicine or its use. Biocelect does not provide medical advice to patients or consumers. You will find information about your medicine in the Consumer Medicine Information below.
Rapivab is indicated for the treatment of acute influenza infection in adults and children 2 years and
older who have been symptomatic for no more than two days*.
Copies of the Product Information and Consumer Medicine Information are available in the links below.
* Current TGA approved indication in Australia. RAPIVAB is currently TGA approved in Australia. RAPIVAB is not approved by MedSafe in New Zealand.